Moreover, GPS monotherapy has been used in the maintenance setting in patients with acute myeloid leukemia (AML) who successfully achieved first or second complete remission, resulting in good tolerance, high frequency of WT1-specific T-cell response, and preliminary evidence of antileukemic activity leading to prolonged OS over historical controls [30,31,32]. Here, WT1 is linked to acute myeloid leukemia.